Nevro Corp. (NVRO)

NYSE: NVRO · IEX Real-Time Price · USD
14.22
-0.34 (-2.34%)
Mar 1, 2024, 4:00 PM EST - Market closed
-2.34%
Market Cap 517.58M
Revenue (ttm) 425.17M
Net Income (ttm) -92.21M
Shares Out 36.40M
EPS (ttm) -2.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 455,981
Open 14.59
Previous Close 14.56
Day's Range 14.12 - 14.61
52-Week Range 13.98 - 39.68
Beta 0.93
Analysts Hold
Price Target 23.09 (+62.38%)
Earnings Date Feb 21, 2024

About NVRO

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implant... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Nov 6, 2014
Employees 1,215
Stock Exchange NYSE
Ticker Symbol NVRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for NVRO stock is "Hold." The 12-month stock price forecast is $23.09, which is an increase of 62.38% from the latest price.

Price Target
$23.09
(62.38% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw

Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint Fusion REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical devi...

4 days ago - PRNewsWire

Nevro Enters Into Cooperation Agreement With Engaged Capital

Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif.

11 days ago - PRNewsWire

Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results

Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif. , Feb. 21, 2024 /PRNewswire/ --Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-...

11 days ago - PRNewsWire

Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy

Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies ...

4 weeks ago - PRNewsWire

Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024

REDWOOD CITY, Calif. , Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa...

4 weeks ago - PRNewsWire

Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy

Spinal Cord Stimulation Coverage Policy to Include 43 Million Additional Covered Lives REDWOOD CITY, Calif. , Jan. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company th...

6 weeks ago - PRNewsWire

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Presentations review clinical results of 10 kHz Therapy™ for the treatment of chronic back and leg pain, non-surgical back pain (NSBP), and painful diabetic neuropathy (PDN) REDWOOD CITY, Calif. , Jan...

6 weeks ago - PRNewsWire

Nevro laying off 63 employees; revenue to beat analyst estimates

Nevro Corp.'s stock NVRO, +5.27% rose by 0.3% in premarket trades on Tuesday after the Redwood City, Calif.-based medical device maker said it would reduce its work force by 5% or 63 people.

7 weeks ago - Market Watch

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results

Fourth-Quarter 2023 Worldwide Revenue Exceeds Company's Expectations Announces Restructuring to Support Company's Long-Term Growth and Profitability REDWOOD CITY, Calif. , Jan. 9, 2024 /PRNewswire/ --...

7 weeks ago - PRNewsWire

Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif. , Jan. 4, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pai...

2 months ago - PRNewsWire

Nevro Announces Acquisition of Vyrsa™ Technologies

Refinances with $200M Structured Debt Maturing in 2029 REDWOOD CITY, Calif. , Nov. 30, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, ...

3 months ago - PRNewsWire

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Data Published in Journal of Neurosurgery: Spine Highlight Lasting Pain Relief, Enhanced Function, Quality of Life, and Reduced Opioid Dependency with High-Frequency SCS Therapy REDWOOD CITY, Calif. ,...

3 months ago - PRNewsWire

Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance

REDWOOD CITY, Calif. , Nov. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pai...

4 months ago - PRNewsWire

Nevro to Report Third Quarter 2023 Financial Results

Company to Host Conference Call on Wednesday, November 1, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , Oct. 4, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company ...

5 months ago - PRNewsWire

New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy

Publications Show Reductions in Hospital Resource Utilization Associated with 10 kHz Therapy Spinal Cord Stimulation for the Treatment of Painful Diabetic Neuropathy and Nonsurgical Refractory Back Pa...

5 months ago - PRNewsWire

Nevro Announces Participation in Upcoming Investor Conferences

REDWOOD CITY, Calif. , Aug. 23, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, anno...

6 months ago - PRNewsWire

New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Evidence Published in Diabetes Research and Clinical Practice Shows 10 kHz Therapy Yields Lasting Pain Relief and Enhances Health-Related Quality of Life and Sleep REDWOOD CITY, Calif. , Aug. 16, 2023...

7 months ago - PRNewsWire

Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance

Company Takes Proactive Steps to Improve Commercial Execution and Maximize Growth Opportunities REDWOOD CITY, Calif. , Aug. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device co...

7 months ago - PRNewsWire

Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference

Abstract Presentations Highlight Durable Pain Relief and Improved Quality of Life for Patients Receiving 10 kHz Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy and Non-Surgical Back Pa...

8 months ago - PRNewsWire

Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference

Wednesday, August 9, 2023 at 8:30 am Eastern Time REDWOOD CITY, Calif. , July 12, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-...

8 months ago - PRNewsWire

Nevro to Report Second Quarter 2023 Financial Results

Company to Host Conference Call on Tuesday, August 1, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , June 27, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company tha...

8 months ago - PRNewsWire

Nevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific Sessions

Presentation to Discuss Correlation Between Use of High-Frequency (10 kHz) Spinal Cord Stimulation and Reductions in HbA1c and Body Weight Nevro to Participate in ADA's Painful Diabetic Neuropathy Sym...

9 months ago - PRNewsWire

Nevro Names New Chief Commercial Officer

Organizational Change Designed to Drive Strong Growth and Advance Global Commercial Focus Company Updates Second Quarter 2023 Revenue Guidance REDWOOD CITY, Calif. , June 5, 2023 /PRNewswire/ -- Nevro...

9 months ago - PRNewsWire

Nevro to Present at Jefferies Healthcare Conference

Thursday, June 8, 2023 at 10:30 am Eastern Time REDWOOD CITY, Calif. , May 22, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-cha...

10 months ago - PRNewsWire

Nevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company Manual

REDWOOD CITY, Calif. , April 27, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic p...

11 months ago - PRNewsWire